Literature DB >> 26798509

Clonal Relatedness among Imipenem-Resistant Pseudomonas aeruginosa Isolated from ICU-Hospitalized Patients.

Hamid Vaez1, Sharareh Moghim1, Bahram Nasr Esfahani1, Hajieh Ghasemian Safaei1.   

Abstract

Imipenem-resistant Pseudomonas aeruginosa (P. aeruginosa) has become an increasingly important problem in healthcare settings worldwide. The aim of the present study was to evaluate clonal spread among imipenem-resistant P. aeruginosa isolated from ICU-hospitalized patients. Totally, 150 wound specimens were analyzed. Antibiotic resistance profiles and clonal diversity were evaluated using Kirby-Bauer's disk diffusion method and Random Amplified Polymorphic DNA- (RAPD-) PCR, respectively. The isolates showed a high frequency of antibiotic resistance against meropenem, and imipenem (100%) followed by ciprofloxacin, and ceftazidime (90%); meanwhile resistance to polymyxin B was not observed. Eighteen (40%) of P. aeruginosa isolates were MBL-positive via ethylenediaminetetraacetic acid (EDTA) combined disk test. Our findings showed high genetic diversity, with 37 different RAPD types detected. RAPD typing results showed cross-acquisition of P. aeruginosa in investigated hospital, suggesting failure in infection control practices. Incidence of MBL-positive isolates is high and should be regarded as a threat to hospitalized patients.

Entities:  

Year:  2015        PMID: 26798509      PMCID: PMC4698532          DOI: 10.1155/2015/983207

Source DB:  PubMed          Journal:  Crit Care Res Pract        ISSN: 2090-1305


1. Introduction

Pseudomonas aeruginosa (P. aeruginosa) is a well-known hospital-acquired pathogen that has been frequently isolated from different kinds of infections such as wound infections, urinary tract infections (UTIs), respiratory tract infections, and blood stream infections (BSI), especially in intensive care unit (ICU) patients [1-3]. Since the antibiotic resistance in P. aeruginosa against different classes of antibiotics is growing rapidly, its treatment is becoming more challenging with each passing year [4]. Carbapenem antibiotics such as imipenem and meropenem were very effective in the treatment of P. aeruginosa infections, when first introduced; however, after less than decade of use resistance to these antibiotics by metallo-β-lactamase- (MBL-) producing strains emerged in clinical settings. A variety of mechanisms of resistance to carbapenems have been observed, including MBL-enzymes, efflux pumps overexpression, OprD mutations, and class D β-lactamases [5, 6]. Treatment of infections caused by imipenem-resistant P. aeruginosa is difficult, owing to the fact that imipenem resistance genes are usually located in transferable genetic elements such as plasmids and integrons along with other antibiotic resistant genes [7, 8]. These observations are consistent with the high mortality and morbidity rates observed among patients infected with imipenem-resistant P. aeruginosa. Moreover production of MBL-enzymes confers resistance to virtually all β-lactam antibiotics, except for monobactam [9]. Molecular epidemiological methods such as Random Amplified Polymorphic DNA- (RAPD-) PCR are well suited to determination of transmission routes of P. aeruginosa in hospital wards [10, 11]. An evaluation of the incidence of imipenem-resistant P. aeruginosa and its transmission in hospitals is of particular importance for the effective management of hospital-acquired infections. The objective of this study was to evaluate the incidence of imipenem-resistant P. aeruginosa in ICU-hospitalized patients and to document the potential for clonal spread.

2. Methods

2.1. Specimen Collection and Bacterial Identification

In total, 150 wound swabs obtained from burned patients admitted to the ICU ward of a referral hospital in Isfahan, between January 2013 and July 2014, were evaluated. Wound infection was identified based on clinical signs, described previously [12]. Only one isolate per patient was included in the study. The study was approved by the ethics committee of the Isfahan University of Medical Sciences (number 392063). Presumptive identification of P. aeruginosa was performed by using standard conventional biochemical test including Gram-staining, catalase, oxidase, pigment production, oxidative-fermentative (OF) tests, and growth at 42°C [13]. Subsequently, species-specific PCR was done using previously designed primer for ITS (16s–23s rRNA internal transcribed spacer) [14]. PCR mixture (25 μL) was made consisting of 200 μM dNTPs, 2.5 mM MgCl2, PCR buffer 1x, Taq DNA pol 1.5 unit (Cinna Gen, Iran), 10 pM of each primer (Metabion, Germany), and 40 ng DNA sample. The following cycling conditions were applied: initial denaturation at 95°C 5 min, 1 cycle, 35 cycles consisting of denaturation at 94°C 1 min, annealing at 58°C 45 s, extension at 72°C 45 s, and final extension at 72°C for 5 min.

2.2. DNA Extraction

Bacterial fresh colonies (two or three) were removed and suspended in 300 mL of lysis buffer containing Tris 100 mM, Nacl 50 mM, and EDTA 25 mM, pH = 7.5, completely. Then suspension was boiled at 95°C for 15 min. Equal volume of phenol/chloroform (25 : 24, pH = 7.5) was added, mixed thoroughly, and centrifuged at 9000 g for 5 min. Aqueous-viscous supernatant was transformed to a new micro tube and phenol/chloroform (25 : 24) was added again and centrifuged for 5 min at 9000 g. 600 μL cold and pure ethanol (Merck, Germany) was added and centrifuged at 13000 g, (4°C-30 min) to precipitate DNA. DNA washed twice in ethanol 70% and after quality check was stored at −20°C.

2.3. Antibiotic Susceptibility Test

Resistance to different antibiotics was tested by Kirby-Bauer's disk diffusion method based on CLSI (Clinical Laboratory Standard Institute) guidelines [15]. The following disks (MAST, UK) were applied: ceftazidime (CAZ, 30 μg), imipenem (IMP, 10 μg), meropenem (MEM, 10 μg), ciprofloxacin (CIP, 5 μg), aztreonam (ATM, 30 μg), polymyxin B (PB, 300 units), and amikacin (AMK, 30 μg). P. aeruginosa standard strain (ATCC 27853) was used as the quality control.

2.4. Detection of MBL

P. aeruginosa isolates that were resistant to imipenem and/or meropenem were subjected to phenotypical detection of MBL-producing isolates by imipenem-EDTA combined disk test, as described earlier [16]. Difference of ≥7 mm between the inhibition-zone diameter of the imipenem-EDTA disk and that of imipenem-only disk was considered as MBL-positive [16]. We used EDTA disk by itself and a strain of P. aeruginosa known to produce VIM-1 metallo-beta-lactamase as the negative and positive control, respectively.

2.5. Random Amplified Polymorphic DNA- (RAPD-) PCR

All P. aeruginosa isolates were submitted to RAPD-genotyping using primer 272-AGCGGGCCAA as previously described [17]. Briefly, optimized PCR mixture was made using 2.5 μL 10x PCR buffer, 2.5 mM MgCl2, 300 μM of dNTPs, 1.7 U Taq DNA polymerase (Cinna Gen, Iran), and 3 μL genomic DNA (40 ng) in 25 μL final volume. The following thermocycler program was used, (1) denaturation 5 min at 95°C, annealing 5 min at 36°C, and elongation 5 min at 72°C, for 4 cycles and (2) 31 cycles consisting of 94°C for 1 min, 45°C for 1 min, and 72°C for 2 min, followed by a final extension at 72°C for 10 min. To ensure reproducibility, each reaction was repeated three times. Similarity between isolates was evaluated based on Dice similarity coefficient and Unweighted Average Pair Group Method (UPGMA), using FreeTree and TreeView software [18, 19]. Only major reproducible bands regardless of intensity were considered for similarity matrix calculation [20] Cut-off value ≥80% was used for determination of potential clonal relatedness [21, 22].

3. Results

Out of 150 tested specimens, 45 (30%) patients had positive culture for P. aeruginosa. Only one isolate per patient was recruited for study. Of the 45 patients, 30 (66%) were females and 15 (34%) were males. The isolates showed a high frequency of antibiotic resistance against meropenem, and imipenem (100%) followed by ciprofloxacin, aztreonam, and ceftazidime (90%), whereas the lowest resistance rate 61.6% was seen against amikacin. Resistance to polymyxin B was not observed. Eighteen (40%) of imipenem-resistant isolates were MBL-positive, using IMP-EDTA combined disk test. This study revealed high diversity of RAPD types, with 37 different RAPD types (Figure 1). Twenty-nine strains of P. aeruginosa showed unique patterns, while the rest of the strains (16) formed 8 distinct clusters. Groups one and three are composed of 2 isolates; these isolates were also MBL-positive.
Figure 1

Dendrogram showing genetic diversity among 45 nonduplicate imipenem-resistant P. aeruginosa by RAPD-PCR.

4. Discussion

Hospitalized patients, particularly those who were admitted to the ICU, are mostly at risk for P. aeruginosa life-threatening infections [23]. Owing to the fact that imipenem resistance genes are usually located in the transposable genetic elements, along with other antibiotic resistance genes [24], the emergence of imipenem-resistant isolates of P. aeruginosa in healthcare settings is a serious problem. In the present study, the highest percentages of resistant isolates were seen against aztreonam, meropenem, ceftazidime, and ciprofloxacin. Although this finding was supported by other studies carried out in Babol province (ceftazidime 92.6%) and Tehran province (imipenem and meropenem 94.7%, ceftazidime 89.4%, and ciprofloxacin 96.2%) of Iran, antibiotic resistance rates reported from Hamadan province (imipenem 7.5%, meropenem 13.2%, and ciprofloxacin 4.7%) were substantially lower than our resistance frequency [25-27]. In addition, our antibiotic resistance rates were significantly higher than those reported from some European countries [28-30]. This higher resistance rate probably resulted from indiscriminate use of antibiotics. According to independent study, presence of some risk factors, including use of catheter, ventilator, and previous consumption of antibiotics are associated with higher antibiotic resistance rates [31]. MBL was observed in 18 (40%) of the 45 imipenem-resistant isolates. This prevalence of MBL is much lower than that reported from other parts of Iran (Tehran province 94% and Zanjan province 87.8%) but is significantly higher than that reported from Sweden (1%) [32-34]. In MBL-negative isolates, probably other mechanisms such as OprD mutations, efflux pumps overexpression, or class D β-lactamase are responsible for carbapenems resistance [35]. In case of use of EDTA as MBL inhibitor due to inhibitory effect on bacterial growth, prevalence of MBL-positive isolates should be reported with precaution because it may lead to false-positive results. Since determining bacterial genetic relatedness is essential for cross-infection evaluation, different genotyping methods have been established [36-39]. In spite of some of the limitations such as difficulty in interpretation of bands in some cases, RAPD-PCR have the advantage of being rapid, simple, and reproducible with high discriminatory power [36-39]. The RAPD-PCR fingerprinting technique yields reliable evaluations of clonal diversity [10, 40]. We detected the high genetic variability, with 37 distinct RAPD types among 45 isolates (82.2% of polymorphisms). Similarly, Silva reported 86 distinct RAPD types (89.6% of polymorphisms) among the 96 strains isolated from clinical specimens of different Brazilian hospitals [41]. In agreement with Pereira study in two referral hospitals of Portugal, our results did not reveal epidemic spread [11]. Our results demonstrate that most of the isolates probably originated from the patients themselves; however, cross-infection of P. aeruginosa between patients is possible to occur, suggesting nosocomial infection control problem.

5. Conclusion

According to our data incidence of imipenem-resistant isolates of P. aeruginosa is in alarming level. Our results did not demonstrate epidemic clone. Probable cross-acquisition has occurred and needs to be considered for future infection control procedure.
  36 in total

1.  Genotyping of Pseudomonas aeruginosa isolated from cockroaches and human urine.

Authors:  Keiko Saitou; Katsunori Furuhata; Masafumi Fukuyama
Journal:  J Infect Chemother       Date:  2010-03-30       Impact factor: 2.211

2.  Virulence attributes in Brazilian clinical isolates of Pseudomonas aeruginosa.

Authors:  Lívia V Silva; Anna Clara M Galdino; Ana Paula F Nunes; Kátia R N dos Santos; Beatriz M Moreira; Luciana C Cacci; Cátia L Sodré; Mariangela Ziccardi; Marta H Branquinha; André L S Santos
Journal:  Int J Med Microbiol       Date:  2014-07-22       Impact factor: 3.473

3.  Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing.

Authors:  Christian G Giske; Balázs Libisch; Céline Colinon; Effie Scoulica; Laura Pagani; Miklós Füzi; Göran Kronvall; Gian Maria Rossolini
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

4.  Genetic diversity of Pseudomonas aeruginosa strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water.

Authors:  R Ruimy; E Genauzeau; C Barnabe; A Beaulieu; M Tibayrenc; A Andremont
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  The influence of Imipenem resistant metallo-beta-lactamase positive and negative Pseudomonas aeruginosa nosocomial infections on mortality and morbidity.

Authors:  Kolhal Veerappa Yogeesha Babu; Divakara Siddanakatte Visweswaraiah; Arun Kumar
Journal:  J Nat Sci Biol Med       Date:  2014-07

Review 6.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

7.  Prevalence and molecular epidemiology of imipenem-resistant Pseudomonas aeruginosa carrying metallo-beta-lactamases from two central hospitals in Portugal.

Authors:  Sónia Gonçalves Pereira; Teresa Reis; Irene Perez Mendez; Olga Cardoso
Journal:  Microb Drug Resist       Date:  2013-06-12       Impact factor: 3.431

8.  Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp but not in Enterobacter spp and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period.

Authors:  H Hanberger; L G Burman; O Cars; M Erlandsson; H Gill; L E Nilsson; D Nordlinder; S M Walther
Journal:  Acta Anaesthesiol Scand       Date:  2007-08       Impact factor: 2.105

9.  Antimicrobial Resistance Patterns and Prevalence of blaPER-1 and blaVEB-1 Genes Among ESBL-producing Pseudomonas aeruginosa Isolates in West of Iran.

Authors:  Mohammad Yousef Alikhani; Zahra Karimi Tabar; Fatemeh Mihani; Enayat Kalantar; Pegman Karami; Mahnaz Sadeghi; Shiva Ahdi Khosroshahi; Safar Farajnia
Journal:  Jundishapur J Microbiol       Date:  2014-01-01       Impact factor: 0.747

10.  Analysis of integrons and associated gene cassettes in clinical isolates of multidrug resistant Pseudomonas aeruginosa from Southwest Nigeria.

Authors:  Bamidele T Odumosu; Bolanle A Adeniyi; Ram Chandra
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-10-21       Impact factor: 3.944

View more
  5 in total

1.  Systematic review and meta-analysis of imipenem-resistant Pseudomonas aeruginosa prevalence in Iran.

Authors:  Hamid Vaez; Amin Salehi-Abargouei; Farzad Khademi
Journal:  Germs       Date:  2017-06-01

Review 2.  Carbapenemase-Producing Non-Glucose-Fermenting Gram-Negative Bacilli in Africa, Pseudomonas aeruginosa and Acinetobacter baumannii: A Systematic Review and Meta-Analysis.

Authors:  Mizan Kindu; Lemma Derseh; Baye Gelaw; Feleke Moges
Journal:  Int J Microbiol       Date:  2020-11-03

3.  Antimicrobial resistance profiles and genetic basis of resistance among non-fastidious Gram-negative bacteria recovered from ready-to-eat foods in Kibera informal housing in Nairobi, Kenya.

Authors:  John Maina; Perpetual Ndung'u; Anne Muigai; John Kiiru
Journal:  Access Microbiol       Date:  2021-06-11

4.  Molecular epidemiology of colistin-resistant Pseudomonas aeruginosa producing NDM-1 from hospitalized patients in Iran.

Authors:  Ahmad Farajzadeh Sheikh; Mojtaba Shahin; Leili Shokoohizadeh; Mehrdad Halaji; Fereshteh Shahcheraghi; Fahimeh Ghanbari
Journal:  Iran J Basic Med Sci       Date:  2019-01       Impact factor: 2.699

5.  Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa.

Authors:  Noha Anwar Hassuna; Marwa K Darwish; Mohamed Sayed; Reham Ali Ibrahem
Journal:  Infect Drug Resist       Date:  2020-01-30       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.